Ghislaine Maxwell Reportedly Thrown Into Solitary Confinement After Saying Epstein Was Murdered

Convicted sex trafficker Ghislaine Maxwell was reportedly punished by authorities at the Federal Correctional Institute Tallahassee over a recorded jailhouse interview that aired in January.

The onetime British socialite, who was accused of procuring underage girls for convicted pedophile Jeffrey Epstein, “was handcuffed and slung into solitary confinement for 48 hours after prison authorities accused her of profiting from a media interview,” the Daily Mail reported Monday.

“She protested her innocence but was marched off to the Special Housing Unit (SHU) — a ‘prison within a prison’ comprising tiny, grim cells where inmates are locked up for 23 hours at a time and fed through slits in the door.”

The news outlet quoted unnamed “insiders” as saying that the inmate they know as “Max” “was just minding her own business when they came in, turned her around and handcuffed her.”

“She got really upset, she was crying, she was yelling that she hadn’t received any money, but nobody saw her again for three days.”

The Mail’s source said, “The SHU is not a nice place.”

“It’s like a little box and you’re only allowed out to shower once a day. There’s no contact from anyone, no privileges, they slide your meals through a slot.”

According to the report, Maxwell’s interview, which was aired Jan. 23 on TalkTV, would have violated the terms of her 20-year federal prison sentence if she received payment for the appearance.

Also in question was how the interview was obtained. As federal prisoner number 02879-509, she is permitted video calls with only those family members and friends on a list approved by the federal prison, according to the report.

She apparently conducted the interviews during phone calls with her friend, filmmaker Daphne Barak.

Maxwell made headlines for several remarks made during those interviews.

One much-publicized comment was that she believed Epstein, contrary to the official narrative, did not commit suicide in his jail cell in 2019.

“I believe that he was murdered,” Maxwell said.

When she heard the news of his death, “I was shocked,” she said. “And I wondered how it had happened. Because as far as I was concerned, he was going to … I was sure he was going to appeal. And I was sure that he was covered under the non-prosecution agreement.”

She also expressed regret for her association with Epstein during the interview. “I honestly wish I’d never met him, you know, looking back now,” she told the interviewer. “I probably wish I had stayed in England.”

Perhaps the most infamous aspect of the widely-publicized January interview was her apparent refusal to issue any sort of apology to the young victims of her crimes.

The best sentiment she could muster was, “I wish them time to heal and to be able to have a productive and good life going forward.”

Maxwell also used the interview to again question the authenticity of a photograph of Prince Andrew, Duke of York, with Virginia Giuffre, who was then a teenager known as Virginia Roberts.

“It’s a fake,” Maxwell insisted. “I don’t believe it’s real for a second, in fact, I’m sure it’s not. There’s never been an original.”

The week after her claim was publicized, the Daily Mail published a story quoting a Florida-based photographic expert as saying he believed the photo to be genuine.

The Mail, which was the first news outlet to publish the photo 12 years ago, said the photo was taken on a Kodak disposable camera and that it was developed at a Walgreens pharmacy in West Palm Beach, Florida, on March 13, 2001.

The photo “was developed at a one-hour lab making it virtually impossible to doctor,” according to the report.

This article appeared originally on The Western Journal.

The post Ghislaine Maxwell Reportedly Thrown Into Solitary Confinement After Saying Epstein Was Murdered appeared first on The Gateway Pundit.

Here We Go: FDA Advisers Recommend World’s First RSV Vaccine from Pfizer

On Tuesday, the Food and Drug Administration’s advisory committee voted in favor of approving the world’s first RSV vaccine for adults 60 and up from Pfizer.

In a close decision, the FDA’s independent Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 7 to 4 on safety and 7 to 4 on effectiveness with one member abstaining.

Several of the specialists who did not vote in favor on the basis of the vaccine’s efficacy were concerned that there were not enough people infected with RSV during the trial to properly evaluate the shot, NBC News reported.

Specialists who voted against the vaccine based on its safety profile were concerned that it might increase the risk of Guillain-Barré syndrome (GBS), a rare neurological disease that can kill nerve cells and lead to muscle weakness or paralysis.

“It was a 1 in 9,000 risk of GBS, which is concerning,” said Dr. Hana El Sahly, the FDA advisory committee chair, who voted against the shot based on its safety profile but in favor based on efficacy.

The VRBPAC claimed that the available data is “adequate to support the safety and effectiveness of its respiratory syncytial virus (RSV) bivalent vaccine candidate PF-06928316 or RSVpreF. ”

“The vaccine candidate is currently under FDA review for the prevention of acute respiratory disease and lower respiratory tract disease caused by RSV in adults 60 years of age and older,” Pfizer said in its news release.

“In older adults, RSV can result in serious illness, hospitalization, or even death, so there is a significant need to protect this at-risk population,” said Annaliesa Anderson, Ph.D., Senior Vice President and Chief Scientific Officer, Vaccine Research and Development, Pfizer. “We are encouraged by the outcome of today’s VRBPAC meeting as it is a testament to the strength of our science and dedication to bringing this important vaccine candidate to the market. We look forward to working with the FDA as it completes the review of our application.”

The FDA will now decide whether or not to approve the vaccine. This process could take months, even though the FDA typically accepts the recommendations of its advisory group. A general rollout of the vaccine is based upon a strong recommendation from the Centers for Disease Control and Prevention (CDC) following FDA approval.

FDA decision expected by PDUFA goal date in May 2023.

The RSV vaccine market for adults will be worth up to $10 billion by 2032, according to Fortune.

The outlet added, “Pfizer is also facing off with collaborators Sanofi and AstraZeneca Plc to develop prevention for dangerous RSV infections in newborns, a market that could reach $1.5 billion, according to projections by Bloomberg Intelligence.”

The Gateway Pundit reported that Pfizer is developing a new vaccine given specifically to pregnant women that will immunize an unborn baby while still in the womb. Pfizer claimed that their infants will be protected against the respiratory syncytial virus (RSV) after birth.

“MATISSE is an ongoing randomized, double-blinded, placebo-controlled Phase 3 study designed to evaluate the efficacy, safety, and immunogenicity of RSVpreF against medically attended lower respiratory tract illness (MA-LRTI) and severe MA-LRTI in infants born to healthy women vaccinated during pregnancy,” Pfizer said.

In the Pfizer study, 7,400 pregnant women were randomly assigned to receive a single dosage of RSVpreF or a placebo during the late second to the third trimester of their pregnancy.

The post Here We Go: FDA Advisers Recommend World’s First RSV Vaccine from Pfizer appeared first on The Gateway Pundit.

About Us

Virtus (virtue, valor, excellence, courage, character, and worth)

Vincit (conquers, triumphs, and wins)